The Numbers Behind Clinical Supply Demand

Every drug that reaches a trial participant passes through a chain that nobody outside the industry thinks about: bulk product is manufactured, split into patient-specific kits, labelled in the languages of every participating country, stored at a controlled temperature, shipped to sites, counted back in, reconciled and finally destroyed. A clinical trial supplies business sells one or more links in that chain to pharmaceutical sponsors, biotech start-ups and contract research organisations. The buyer is rarely a consumer. It is a clinical supply manager at a sponsor who is judged on one thing: no site ever runs out of drug.

MarketsandMarkets sizes the global clinical trial supplies market at $5.34 billion in 2025, rising to $8.18 billion by 2030, a compound annual growth rate of 8.9% (MarketsandMarkets, 2025). The same publisher's earlier reading puts 2024 at $4.85 billion, and attributes 41.4% of that revenue to North America, with decentralised trials and cold-chain logistics named as the main growth drivers.

Treat any single figure with caution. Published estimates for 2025 range from about $4.0 billion to $5.96 billion depending on whether the publisher counts logistics-only players, packaging-only players or both (Mordor Intelligence; Polaris Market Research). What matters for a lender or investor reading your plan is that every credible source lands in a growth band of roughly 7.8% to 9.1% a year, so your plan should not assume a faster market than that. If your forecast needs 20% market growth to work, the plan is weak, not the market.

Where the revenue actually sits

Logistics and distribution is the largest service line. Published breakdowns give it between roughly 30% and 37% of 2025 revenue, ahead of packaging, labelling, storage and manufacturing. The fastest-growing line is comparator sourcing, forecast at an 11.2% CAGR, because sponsors running head-to-head studies need a marketed competitor drug in their own packaging and nobody wants to buy it at retail. That one number is worth building a pricing line around: a new entrant that cannot afford a GMP packaging suite can still win business buying, relabelling under a qualified partner and documenting comparator product.

The named incumbents are worth knowing because your sponsors already use them. Thermo Fisher Scientific (through its Fisher Clinical Services business), Almac Group, Catalent, Biocair, KLIFO and Movianto appear in every market report. At the cold-storage end, Patheon runs a cryogenic facility in Frederick, Maryland and Sharp Services offers validated frozen storage down to minus 80 degrees Celsius. None of them wants a sponsor with a 40-patient Phase 1 study and a $300,000 supply budget. That gap, small and mid-sized studies that large depots treat as an afterthought, is where independents survive.

The waste problem is your sales pitch

Clinical supply is unusually wasteful, and the data is specific. Work from the Tufts Center for the Study of Drug Development, quoted by planning-software vendors, suggests up to 40% of comparator drug supply can go unused. A review of 57 studies across 12 companies found 67.8% of shipped product was dispensed, so roughly 32% never reached a patient. A separate review of 200 studies reported that 62% of the material packaged and released went unused (N-SIDE; Clinical Leader). One worked example in the trade press: a 100-site, 1,000-patient study needing 12,000 kits at $100 each saves $1.8 million if a 50% overage is enough where the original forecast assumed 200% (Clinical Trials Arena).

For a business plan, this is the commercial insight: a supplier that reduces overage is selling money back to the sponsor, and that is an easier conversation than selling a cheaper per-kit price. On-demand, late-stage labelling is reported to cut manufacturing waste by 20% to 60% by avoiding pre-built inventory that expires or gets destroyed. If your model includes a small-batch, just-in-time labelling suite, say so in the executive summary and put the saving in a table, not an adjective.

One more demand-side point. The market reports consistently cite decentralised and hybrid trials as a driver. A direct-to-patient shipment is a different product from a site shipment: smaller, more frequent, temperature-excursion-sensitive, and requiring a courier who will hand it to a participant at home. Plans that describe a direct-to-patient service line with named courier partners and a returns process look materially more current than plans that describe only site-to-site freight.

In the UK, the clinical trials regulatory reforms have kept sponsors interested in running studies at NHS sites, which feeds local demand for depot, labelling and courier services. We do not put a UK-specific market size on that, because no publisher we found separates a reliable UK supplies figure. Your plan should do the same: state the global figure with its source, then build the UK or US serviceable market bottom-up from the number of studies you can realistically win in year one and the average supply budget per study.

Three Ways to Run a Clinical Supplies Company

"Clinical trial supplies" is not one business. Founders who blur the models end up pricing a brokerage like a GMP site or the reverse. Pick the model first; the licences, capital and sales cycle follow from it. The figures below are Avvale modelling estimates built from supplier quotes and sector benchmarks, not published statistics, so replace them with your own quotes before showing a lender.

Model A is where most founders with industry backgrounds should start. A former clinical supply manager at a mid-sized sponsor already knows how a forecast is built, which IRT (interactive response technology) vendors are used, and where the invoices disagree with the contract. Model A needs a laptop, professional indemnity insurance and two or three vendor agreements. It also builds the client list that a depot or packaging line would later need, which is why many plans stage A into B into C over four years rather than committing $3 million on day one.

Model B is the quietest business of the three. A GDP depot in a regional hub sells floor space, validated cold rooms and courier lanes. Its profit is decided by occupancy: a cold room that is 70% full is a business; one at 35% is a hobby with a lease. Model C has the highest ceiling and the cruellest utilisation curve, because a packaging line costs nearly as much idle as running, and studies arrive in lumps. A plan for C must show a pipeline by study, not an average monthly volume.

A fourth hybrid is worth a paragraph in your plan if you have access to capital but not to a building: rent time on a contract packager's line under your own quality system and brand. You sell the kit, they provide the room. Margins are lower than owning the line, but the licences sit with the partner and you can reach revenue in under a year.

What It Costs to Open the Doors

The three models above cost very different amounts, so a single "typical start-up cost" is useless in a lender's hands. This section prices Model B in detail because it is the model where the cost structure is least obvious, then notes the differences for A and C.

Line items that surprise first-time founders

• Qualification is a cost, not a formality. Installation, operational and performance qualification of every cold room and the monitoring system, plus temperature mapping across seasons, is routinely a fifth of the build budget. Sponsors will ask to see the reports during audit.
• Ultra-cold is a different order of magnitude. One warehousing cost guide puts a minus 80C bank of 40 to 80 freezers at $1.2M to $3.4M to build, $140K to $420K to validate and $120K to $340K a year to monitor (Warehousing Costs, 2026). The same guide lists minus 80C storage at $240 to $520 per pallet per month. A plan that includes ultra-cold on day one without a signed anchor customer is a plan lenders decline.
• Controlled-drug storage. A secured, alarmed cage with access logging and a DEA registration for research use (the researcher registration fee is listed at $296 a year) is cheap compared with the building but slow to approve. Budget calendar time, not just dollars.
• Insurance. Stock-in-trade cover for investigational product is expensive because one freezer failure can destroy product worth more than your whole balance sheet. Some sponsors insist on specific limits per shipment; get quotes before you set your fee schedule.
• Software. A warehouse management system with lot, expiry and temperature-chain tracking, an eQMS, and an interface to the sponsor's IRT platform. Planning tools such as N-SIDE and trialsupply.co show the kind of forecasting a sponsor expects you to understand even if you do not sell it.
• Validated shippers. Passive and active shippers are bought in volume or rented per shipment. Major providers publish no rate card, so the only honest number in your plan is a quote from at least two couriers for your actual lanes.

Model A and Model C in one paragraph each

Model A is mostly working capital and insurance. A realistic budget is $90K to $250K: company set-up, professional indemnity cover, a quality manual, two audited vendor relationships, a website that does not look like a template, travel to two industry conferences and six months of founder salary. Model C starts at roughly $2.5M and runs past $6M once a blinding suite, serialisation-ready labelling equipment, a clean packaging room, a QP retained under contract and eighteen months of payroll are included. Neither of those numbers is a published benchmark; they are planning ranges for you to replace with quotes.

Funding routes, in the order lenders look at them

For a US founder, an SBA 7(a) loan can fund equipment, leasehold improvements and working capital, but lenders want a personal guarantee, 10% to 20% equity injection and evidence that someone on your team has operated a GMP or GDP facility before. Model C usually needs an equity round plus equipment financing rather than a single loan. For a UK founder, a Start Up Loan covers a small Model A launch; anything larger usually pairs a bank facility with SEIS or EIS-eligible equity, and Innovate UK grants are worth checking where your service touches advanced therapies. Whichever route you choose, a signed letter of intent from one sponsor or CRO changes the lender conversation more than any forecast.

If you want a lender-ready version of this section built for your own numbers, the Research + Content package covers market research, narrative and cost tables in three to four days.

Where to Locate: Regional Hubs and What They Charge You

Clinical supply businesses are tied to airports, to pharmaceutical clusters and to the courier lanes that serve them. The map below is qualitative: it describes why a region works, not what rent costs, because commercial rents for validated space shift too quickly to print.

Two location rules save more money than any rent negotiation. First, sit within a short, reliable courier run of a major cargo airport; a depot that adds a day to every international shipment loses to a competitor 30 minutes from the airport regardless of price. Second, confirm that the building has backup power capacity before you sign: a generator that cannot carry the cold rooms for 48 hours is a defect that appears in every audit.

If you operate from the UK and sell to EU sponsors, remember that post-Brexit you need an EU-based Qualified Person and, for importation of investigational product into the EU, an authorised importer. Many UK entrants therefore partner with a Belgian or Dutch depot rather than building their own, and show that partnership as a line in the plan.

How Clinical Supply Revenue Is Built, Line by Line

Sponsors do not buy "supply services" as a bundle. They buy a statement of work with fixed and variable lines, and the margin differs sharply between them. A plan that shows a single blended price per study hides the structure lenders want to see.

A worked example: one Phase 2 study, start to finish

The numbers below are an illustrative model, not a market quote. A sponsor runs a 160-patient, 24-week study at 14 sites in three countries. Participants collect a four-week kit at each visit, so six kits per patient: 960 kits. The sponsor forecasts a 40% overage for late enrolment and re-supply, bringing the packaged total to 1,344 kits. The pricing is built as follows.

• Kit packaging at $38 per kit across 1,344 kits: $51,072
• Label design and translation into five languages: $9,500
• Storage of four pallets in a 2-8C room for 14 months at an assumed $75 per pallet-month: $4,200
• 168 site shipments (14 sites, 12 re-supplies each) at a blended $410: $68,880
• Project management, 22 hours a month for 14 months at $145: $44,660
• Two QP batch releases at $3,800: $7,600
• Returns, reconciliation and destruction: $6,200

The statement of work totals $192,112. If direct costs (labour, courier freight, consumables, QP fees) run at 62%, gross profit is about $73,000, a 38% margin. Now apply the waste data from earlier. If forecasting and IRT-driven re-supply allow the sponsor to cut overage from 40% to 25%, packaged kits fall to 1,200 and your packaging revenue drops by $5,472, but you have saved the sponsor roughly $14,400 of drug at a $100-equivalent kit cost and you have a reference for the next study. Plans that show this trade-off explicitly read as credible, because the founder understands the client's economics and not just their own.

A business doing eight studies of this size in a year earns roughly $1.5M in revenue. Overheads for a Model B depot (rent, quality staff, insurance, software, monitoring) will consume $450K to $650K of that, which is why the plan must show a realistic ramp: two or three studies in year one, five to six in year two, eight to ten by year three.

Unit economics that lenders test first

• Occupancy. Break-even for a cold room is usually between 55% and 65% occupied pallet positions. State your break-even occupancy and the month you reach it.
• Revenue per employee. Quality-heavy operations support $140K to $220K of revenue per head; below that, either pricing or utilisation is wrong.
• Customer concentration. Most new depots rely on one or two sponsors in year one. Show the revenue if the largest client leaves. Lenders will ask.
• Working capital for comparators. If you buy comparator product on behalf of a sponsor, decide whether the sponsor pre-pays. Carrying a $400,000 pallet of marketed drug on your balance sheet for ninety days is not a rounding error.

Licences, Registrations and Labelling Law in the US, UK and EU

Regulation is the moat in this business. It is also the main reason plans get rejected, because founders list "licences" as a single line when each jurisdiction asks different questions. Confirm every point below with a regulatory consultant or the relevant authority before you commit capital; this is orientation, not legal advice.

United States

• Investigational drug labelling, 21 CFR 312.6. Every investigational drug label must carry the statement "Caution: New Drug, Limited by Federal (or United States) law to investigational use." Your labelling suite must be able to print that statement, and your quality system must show who approves label text before printing.
• Labelling mock-ups in the IND. Under 21 CFR 312.23(a)(7)(iv)(d), a mock-up or printed representation of the proposed labelling is submitted with the sponsor's application. Sponsors will send you the approved text; your job is to reproduce it exactly (FDA IND content and format guidance).
• CGMP for Phase 1 products. FDA's 2008 guidance explains that the full CGMP regulations are not required for most Phase 1 investigational drugs, but the statutory CGMP expectation still applies through the approach set out in the guidance (FDA Phase 1 CGMP guidance). In practice, sponsors still audit packagers against phase-appropriate GMP, so plan for it.
• DEA registration for controlled substances. Research registration for Schedule II to V uses DEA Form 225 (new) or 225a (renewal), with a listed fee of $296 and a one-year term, and a separate registration is needed for each location where controlled substances are stored (21 CFR 1301.13). Many sponsors will not give you opioid or stimulant studies until you hold it.
• State-level licensing. Whether your depot needs a wholesale distributor or third-party logistics licence varies by state, and some states exempt investigational product while others do not. Ask the board of pharmacy in the state where your depot sits, in writing, and keep the reply in your quality file.

United Kingdom

• MIA(IMP). Assembling, packaging and labelling investigational medicinal products in the UK generally requires a Manufacturer's Authorisation for IMPs from the MHRA, with a named Qualified Person. This is the licence that separates Model C from Models A and B.
• Wholesale dealer's authorisation. A depot that stores and distributes medicines typically needs a Wholesale Dealer's Authorisation and a Responsible Person for GDP. Check with the MHRA whether your specific activity, such as storing product for a single sponsor under their authorisation, changes the requirement.
• Why client budgets matter to you. The MHRA charges sponsors a fee of £4,656 for a clinical trial application that includes an IMP dossier, with initial assessment in 30 days and a final decision usually within 60 (NIAID ClinRegs, UK profile). That fee is not yours to pay, but it tells you how a small sponsor's regulatory budget is shaped before supply is even discussed.
• New regulations. The MHRA announced a pilot running from 1 October 2025 to 31 March 2026 ahead of new clinical trials regulations scheduled to apply from 28 April 2026 (Clinical Trials Arena). Check the current text before you finalise any UK compliance section, because labelling and notification duties can change.

European Union

• Labelling under Annex VI. Regulation (EU) No 536/2014 puts IMP labelling requirements in Annex VI, replacing the older GMP Annex 13 approach. A notable change: studies under the Clinical Trials Regulation require the expiry date on the immediate packaging without exception, where Annex 13 allowed it to be omitted in certain cases (ECA Academy). If your equipment prints labels on outer cartons only, you need an upgrade.
• Qualified Person certification. A QP certifies that each batch manufactured in or imported into the Union complies with Article 63, and a second step follows: the sponsor verifies QP certification and clinical trial authorisation before delivery to sites (European Commission, CTCG Q&A). Your plan must name the QP, show their contract and describe how release decisions are recorded.
• Importation. Product moving from the UK or US into the EU needs an authorised importer. Plans that skip this step are common among UK founders targeting EU sponsors.

A final point on regulation and reputation: sponsors audit you before they award work, and the audit report is your most valuable sales document. Plan one third-party GDP or GMP audit in year one, budget for it, and show it in the timeline. A clean audit from a recognised consultant often replaces six months of sales calls.

Six Mistakes That Sink New Entrants

These come from patterns that repeat in supply-chain start-ups, not from any single company. Each one belongs in your risk section, with a mitigation.

1. Pricing like a freight company

Freight is the part of the statement of work with the thinnest margin. Founders who build their model around per-shipment revenue find that courier costs rise faster than their quotes. Anchor margin in project management, documentation, quality and storage, and treat freight as pass-through with a handling fee.

2. Underestimating validation time

Temperature mapping and qualification can take three to six months from the day the room is built. If your revenue forecast starts the day the lease starts, the first year is wrong. Show the gap between lease start and first billable pallet.

3. Selling to the wrong buyer

The person who signs is usually the sponsor's clinical supply or procurement lead, but the person who can kill the deal is quality assurance. A pitch that skips the quality conversation until the contract stage loses months. Put a quality-led sales step in your plan.

4. Carrying comparator inventory on your own balance sheet

Buying marketed drug on behalf of a sponsor creates large invoices with short payment terms from the manufacturer or distributor. If the sponsor pays in sixty days and your supplier wants payment in thirty, you finance the difference. Require pre-payment or a deposit, and show it in the cash-flow table.

5. Ignoring the waste conversation

If studies waste a third or more of shipped product and you do nothing to address it, you are a commodity vendor. If your plan reduces overage through better forecasting, on-demand labelling or returns reconciliation, you are a partner. Waste reduction is both a service line and a differentiator.

6. One-client dependence

A single Phase 1 sponsor can fund a first year, then disappear when the study finishes. Plan a pipeline of at least four named prospects, show expected study start dates, and include a downside case where your largest client leaves after month nine.

Glossary for Sponsor Conversations

Using the right terms in your plan signals experience. Misusing them signals the opposite.

• IMP: investigational medicinal product, the study drug or placebo or comparator being tested.
• IRT (or IWRS/IVRS): the randomisation and supply management system that tells sites which kit number to dispense and triggers re-supply.
• QP: Qualified Person, the individual legally responsible for certifying that a batch meets requirements before release in the UK and EU.
• GDP and GMP: Good Distribution Practice (storage and transport) and Good Manufacturing Practice (production, packaging, labelling).
• Comparator: a marketed product used as the control in a study, often sourced and relabelled by the supplier.
• Overage: extra kits packaged beyond the forecast to cover uncertainty; the lever that decides how much waste a study produces.
• Temperature excursion: a period outside the labelled storage range, which must be assessed and documented before the product can be used.
• Direct-to-patient (DtP): shipment from the depot to a participant's home in a decentralised or hybrid trial.

Sample Plan Extract: Meridian Clinical Supply Partners

This is an excerpt in the style of the finished plan, for a fictional Model A business. It shows the level of specificity lenders expect.

The full template lays out the same structure with prompts under each heading, so you replace the fictional figures with your own quotes and study pipeline.

What Is Inside the Template

The template is built around how supply-chain buyers read a proposal, not around a generic start-up outline. Each section carries guidance specific to this sector.

• Executive summary: which model (A, B or C), which study sizes, which therapeutic areas.
• Service catalogue: packaging, labelling, storage, shipment, DtP, returns and destruction, each with a pricing basis.
• Quality system: GDP and GMP approach, CAPA, deviations, audit schedule and QP arrangements.
• Market and sponsor segments: virtual biotech, mid-sized pharma, CROs, with named competitors and positioning against them.
• Operations plan: site, equipment, qualification timeline, courier lanes and contingency for a freezer failure.
• Regulatory plan: licences by jurisdiction with application dates and responsible people.
• Financial model: occupancy-driven revenue, study-by-study pipeline, working capital, 5-year forecast (in the paid packages).
• Risk register: temperature excursion, single-client dependence, regulatory change, QP unavailability.

To see how adjacent sectors are handled, read the plan templates for clinical trial packaging, clinical manufacturing services and biopharmaceutical start-ups. If your intended sponsors are early-stage drug developers, these sit next to the sections above. The wider library lives on the free business plan template hub.

Questions Founders Ask